Evidence map›Paper›PMID 30661301›Full record

ArticleTransboundary and emerging diseases2019

Evidence of reduced viremia, pathogenicity and vector competence in a re-emerging European strain of bluetongue virus serotype 8 in sheep.

John Flannery, Beatriz Sanz-Bernardo, Martin Ashby, Hannah Brown, Simon Carpenter, Lyndsay Cooke, Amanda Corla, Lorraine Frost, Simon Gubbins, Hayley Hicks and 9 more

Open access · hybridAbstract read
In one paragraph

Article in Transboundary and emerging diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
9.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Longitudinal seroepidemiological survey and risk factors for bluetongue virus infection in sheep in the state of Parana, Brazil, from 2014 to 2017.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Article
  9. Increased Virulence ofViruses · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 2 countries.

John FlanneryThe Pirbright Institute, Pirbright, UK.ORCID https://orcid.org/0000-0002-5012-2829
Beatriz Sanz-BernardoThe Pirbright Institute, Pirbright, UK.
Martin AshbyThe Pirbright Institute, Pirbright, UK.
Hannah BrownThe Pirbright Institute, Pirbright, UK.
Simon CarpenterThe Pirbright Institute, Pirbright, UK.
Lyndsay CookeThe Pirbright Institute, Pirbright, UK.
Amanda CorlaThe Pirbright Institute, Pirbright, UK.
Lorraine FrostThe Pirbright Institute, Pirbright, UK.
Simon GubbinsThe Pirbright Institute, Pirbright, UK.ORCID https://orcid.org/0000-0003-0538-4173
Hayley HicksThe Pirbright Institute, Pirbright, UK.
Mehnaz QureshiThe Pirbright Institute, Pirbright, UK.
Paulina Rajko-NenowThe Pirbright Institute, Pirbright, UK.
Christopher SandersThe Pirbright Institute, Pirbright, UK.
Matthew TullyThe Pirbright Institute, Pirbright, UK.
Emmanuel BréardUniversité Paris-Est ANSES Alfort, UMR 1161 ANSES/INRA/ENVA,, Maisons-Alfort, France.ORCID https://orcid.org/0000-0002-0512-0779
Corinne SailleauUniversité Paris-Est ANSES Alfort, UMR 1161 ANSES/INRA/ENVA,, Maisons-Alfort, France.ORCID https://orcid.org/0000-0001-9077-6934
Stephan ZientaraUniversité Paris-Est ANSES Alfort, UMR 1161 ANSES/INRA/ENVA,, Maisons-Alfort, France.
Karin DarpelThe Pirbright Institute, Pirbright, UK.
Carrie BattenThe Pirbright Institute, Pirbright, UK.
The Pirbright Institute · GBÉcole Nationale Vétérinaire d'Alfort · FR

Funding

Biotechnology and Biological Sciences Research Council BBS/E/I/00007033Biotechnology and Biological Sciences Research Council BBS/E/I/00007036Biotechnology and Biological Sciences Research Council BBS/E/I/00007037Biotechnology and Biological Sciences Research Council (BBSRC) BBS/E/I/00007030Biotechnology and Biological Sciences Research Council (BBSRC) BBS/E/I/00007033Biotechnology and Biological Sciences Research Council (BBSRC) BBS/E/I/00007036Biotechnology and Biological Sciences Research Council (BBSRC) BBS/E/I/00007037Department for Environment, Food and Rural Affairs (Defra) SE2621European Commission
6 · The paper itself

Abstract

The outbreak of bluetongue virus (BTV) serotype 8 (BTV-8) during 2006-2009 in Europe was the most costly epidemic of the virus in recorded history. In 2015, a BTV-8 strain re-emerged in France which has continued to circulate since then. To examine anecdotal reports of reduced pathogenicity and transmission efficiency, we investigated the infection kinetics of a 2007 UK BTV-8 strain alongside the re-emerging BTV-8 strain isolated from France in 2017. Two groups of eight BTV-naïve British mule sheep were inoculated with 5.75 log

Indexed as

AnimalsAntibodies, ViralBluetongueBluetongue virusCeratopogonidaeCommunicable Diseases, EmergingDisease OutbreaksFemaleFranceInsect VectorsSerogroupSheepViremiaVirulenceAntibodies, Viralarbovirusesbluetongue virusEuropean serotypesinfection kineticsvirus isolation RT-qPCR

Identifiers

PMID30661301
PMCPMC6563110
OpenAlexW2901175304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.